Table 5 Association between cardiovascular comorbidities and the use of Methotrexate and Leflunomide
Methotrexate | Leflunomide | ||||||
|---|---|---|---|---|---|---|---|
Yes n*(%) | PRˆ (IC95%) | p‡ | Yes n*(%) | PRˆ (IC95%) | p‡ | ||
Cardiovascular Comorbidities | Yes | 463 (62.4) | 0.945 (0.862–1.036) | 0.232 | 251 (66.4) | 1.068 (0.975–1.170) | 0.167 |
No | 279 (37.6) | 1.107 (0.935–1.311) | 127 (33.6) | 0.889 (0.750–1.053) | |||
Systemic Arterial Hypertension | Yes | 365 (49.2) | 0.958 (0.847–1.083) | 0.499 | 195 (51.6) | 1.052 (0.931–1.188) | 0.423 |
No | 377 (50.8) | 1.044 (0.921–1.184) | 183 (48.4) | 0.950 (0.838–1.078) | |||
Dyslipidemia | Yes | 236 (31.8) | 0.937 (0.785–1.117) | 0.469 | 129 (34.1) | 1.076 (0.903–1.283) | 0.414 |
No | 506 (68.2) | 1.033 (0.946–1.127) | 249 (65.9) | 0.965 (0.884–1.053) | |||
Diabetes Mellitus | Yes | 111 (15) | 1.017 (0.755–1.371) | 0.910 | 52 (13.8) | 0.891 (0.657–1.207) | 0.453 |
No | 631 (85) | 0.997 (0.947–1.050) | 326 (86.2) | 1.020 (0.970–1.073) | |||
Congestive Heart Failure | Yes | 18 (2.4) | 1.512 (0.605–3.777) | 0.372 | 7 (1.9) | 0.804 (0.336–1.922) | 0.623 |
No | 724 (97.6) | 0.992 (0.975–1.009) | 371 (98.1) | 1.005 (0.987–1.023) | |||
Cerebrovascular Disease | Yes | 14 (1.9) | 0.706 (0.316–1.574) | 0.392 | 9 (2.4) | 1.171 (0.517–2.652) | 0.704 |
No | 728 (98.1) | 1.008 (0.989–1.028) | 369 (97.6) | 0.996 (0.978–1.015) | |||
Acute Myocardial Infarction | Yes | 12 (1.6) | 1.210 (0.429–3.408) | 0.718 | 3 (0.8) | 0.418 (0.121–1.447) | 0.200 |
No | 730 (98.4) | 0.997 (0.982–1.012) | 375 (99.2) | 1.011 (0.998–1.025) | |||
Peripheral Vascular Disease | Yes | 5 (0.7) | 0.840 (0.202–3.496) | 1.000 | 5 (1.3) | 3.254 (0.782–13.543) | 0.129 |
No | 737 (99.3) | 1.001 (0.990–1.012) | 373 (98.7) | 0.991 (0.970–1.003) | |||